T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

NCT04093648 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The key elements of this study were incorporated into another study.

Conditions

Hepatocellular Carcinoma
Hepatoblastoma

Interventions

GENETIC: TEGAR T cells
DRUG: Cytoxan
DRUG: Fludarabine

Sponsor

Baylor College of Medicine

Collaborators

[object Object]